nodes	percent_of_prediction	percent_of_DWPC	metapath
Torasemide—PTGS1—Etoposide—urinary bladder cancer	0.142	0.316	CbGbCtD
Torasemide—CYP2C8—Fluorouracil—urinary bladder cancer	0.0982	0.219	CbGbCtD
Torasemide—CYP2C8—Etoposide—urinary bladder cancer	0.0819	0.183	CbGbCtD
Torasemide—CYP2C9—Fluorouracil—urinary bladder cancer	0.0685	0.153	CbGbCtD
Torasemide—CYP2C9—Cisplatin—urinary bladder cancer	0.0582	0.13	CbGbCtD
Torasemide—SLC12A1—urine—urinary bladder cancer	0.0375	0.247	CbGeAlD
Torasemide—CYP2C19—urine—urinary bladder cancer	0.0182	0.12	CbGeAlD
Torasemide—CYP2C9—urine—urinary bladder cancer	0.0141	0.0931	CbGeAlD
Torasemide—SLC12A1—prostate gland—urinary bladder cancer	0.0134	0.0886	CbGeAlD
Torasemide—SLC12A1—epithelium—urinary bladder cancer	0.00988	0.0651	CbGeAlD
Torasemide—SLC12A1—renal system—urinary bladder cancer	0.00916	0.0604	CbGeAlD
Torasemide—SLC12A1—urethra—urinary bladder cancer	0.009	0.0593	CbGeAlD
Torasemide—PTGS1—prostate gland—urinary bladder cancer	0.00463	0.0305	CbGeAlD
Torasemide—PTGS1—seminal vesicle—urinary bladder cancer	0.00392	0.0258	CbGeAlD
Torasemide—CYP2C8—renal system—urinary bladder cancer	0.00389	0.0256	CbGeAlD
Torasemide—Musculoskeletal discomfort—Valrubicin—urinary bladder cancer	0.00341	0.0119	CcSEcCtD
Torasemide—PTGS1—epithelium—urinary bladder cancer	0.0034	0.0224	CbGeAlD
Torasemide—PTGS1—smooth muscle tissue—urinary bladder cancer	0.00328	0.0216	CbGeAlD
Torasemide—CYP2C19—vagina—urinary bladder cancer	0.00323	0.0213	CbGeAlD
Torasemide—PTGS1—renal system—urinary bladder cancer	0.00316	0.0208	CbGeAlD
Torasemide—CYP2C8—female reproductive system—urinary bladder cancer	0.00312	0.0205	CbGeAlD
Torasemide—Hyperuricaemia—Cisplatin—urinary bladder cancer	0.00307	0.0107	CcSEcCtD
Torasemide—Pain—Carboplatin—urinary bladder cancer	0.00296	0.0104	CcSEcCtD
Torasemide—Blood uric acid increased—Cisplatin—urinary bladder cancer	0.0029	0.0101	CcSEcCtD
Torasemide—Syncope—Mitomycin—urinary bladder cancer	0.00283	0.0099	CcSEcCtD
Torasemide—Leukopenia—Mitomycin—urinary bladder cancer	0.00282	0.00988	CcSEcCtD
Torasemide—CYP2C8—vagina—urinary bladder cancer	0.00282	0.0186	CbGeAlD
Torasemide—Hyperuricaemia—Etoposide—urinary bladder cancer	0.00281	0.00983	CcSEcCtD
Torasemide—Loss of consciousness—Mitomycin—urinary bladder cancer	0.00277	0.0097	CcSEcCtD
Torasemide—CYP2C9—female reproductive system—urinary bladder cancer	0.00277	0.0182	CbGeAlD
Torasemide—Cough—Mitomycin—urinary bladder cancer	0.00275	0.00963	CcSEcCtD
Torasemide—Asthenia—Valrubicin—urinary bladder cancer	0.00268	0.00938	CcSEcCtD
Torasemide—Blood uric acid increased—Etoposide—urinary bladder cancer	0.00266	0.00929	CcSEcCtD
Torasemide—Oedema—Mitomycin—urinary bladder cancer	0.00258	0.00901	CcSEcCtD
Torasemide—Diarrhoea—Valrubicin—urinary bladder cancer	0.00256	0.00894	CcSEcCtD
Torasemide—PTGS1—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00254	0.0224	CbGpPWpGaD
Torasemide—Shock—Mitomycin—urinary bladder cancer	0.00253	0.00886	CcSEcCtD
Torasemide—PTGS1—female reproductive system—urinary bladder cancer	0.00253	0.0167	CbGeAlD
Torasemide—Thrombocytopenia—Mitomycin—urinary bladder cancer	0.00252	0.00882	CcSEcCtD
Torasemide—Dizziness—Valrubicin—urinary bladder cancer	0.00247	0.00864	CcSEcCtD
Torasemide—Dehydration—Thiotepa—urinary bladder cancer	0.00245	0.00857	CcSEcCtD
Torasemide—CYP2C9—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00241	0.0212	CbGpPWpGaD
Torasemide—Vomiting—Valrubicin—urinary bladder cancer	0.00238	0.00831	CcSEcCtD
Torasemide—Rash—Valrubicin—urinary bladder cancer	0.00236	0.00824	CcSEcCtD
Torasemide—Dermatitis—Valrubicin—urinary bladder cancer	0.00235	0.00824	CcSEcCtD
Torasemide—Headache—Valrubicin—urinary bladder cancer	0.00234	0.00819	CcSEcCtD
Torasemide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—urinary bladder cancer	0.0023	0.0203	CbGpPWpGaD
Torasemide—PTGS1—vagina—urinary bladder cancer	0.00229	0.0151	CbGeAlD
Torasemide—Nausea—Valrubicin—urinary bladder cancer	0.00222	0.00777	CcSEcCtD
Torasemide—Pain—Mitomycin—urinary bladder cancer	0.0022	0.0077	CcSEcCtD
Torasemide—Gastrointestinal haemorrhage—Fluorouracil—urinary bladder cancer	0.00218	0.00762	CcSEcCtD
Torasemide—Hyponatraemia—Cisplatin—urinary bladder cancer	0.00207	0.00725	CcSEcCtD
Torasemide—Gastrointestinal haemorrhage—Cisplatin—urinary bladder cancer	0.00207	0.00723	CcSEcCtD
Torasemide—Hyperglycaemia—Thiotepa—urinary bladder cancer	0.00205	0.00718	CcSEcCtD
Torasemide—Hypokalaemia—Gemcitabine—urinary bladder cancer	0.00202	0.00706	CcSEcCtD
Torasemide—Toxic epidermal necrolysis—Gemcitabine—urinary bladder cancer	0.002	0.00698	CcSEcCtD
Torasemide—Dehydration—Cisplatin—urinary bladder cancer	0.00192	0.00672	CcSEcCtD
Torasemide—Hypokalaemia—Cisplatin—urinary bladder cancer	0.00188	0.00658	CcSEcCtD
Torasemide—Asthenia—Mitomycin—urinary bladder cancer	0.00185	0.00646	CcSEcCtD
Torasemide—Haemoglobin—Thiotepa—urinary bladder cancer	0.00183	0.00641	CcSEcCtD
Torasemide—Haemorrhage—Thiotepa—urinary bladder cancer	0.00182	0.00638	CcSEcCtD
Torasemide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00182	0.016	CbGpPWpGaD
Torasemide—PTGS1—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00178	0.0157	CbGpPWpGaD
Torasemide—Diarrhoea—Mitomycin—urinary bladder cancer	0.00176	0.00616	CcSEcCtD
Torasemide—Pancreatitis—Cisplatin—urinary bladder cancer	0.00175	0.00612	CcSEcCtD
Torasemide—Hyperglycaemia—Gemcitabine—urinary bladder cancer	0.00173	0.00604	CcSEcCtD
Torasemide—Toxic epidermal necrolysis—Etoposide—urinary bladder cancer	0.0017	0.00596	CcSEcCtD
Torasemide—Dizziness—Mitomycin—urinary bladder cancer	0.0017	0.00596	CcSEcCtD
Torasemide—Stevens-Johnson syndrome—Gemcitabine—urinary bladder cancer	0.00169	0.00592	CcSEcCtD
Torasemide—Hyperuricaemia—Methotrexate—urinary bladder cancer	0.00168	0.00589	CcSEcCtD
Torasemide—CYP2C8—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00164	0.0145	CbGpPWpGaD
Torasemide—Vomiting—Mitomycin—urinary bladder cancer	0.00164	0.00573	CcSEcCtD
Torasemide—Rash—Mitomycin—urinary bladder cancer	0.00162	0.00568	CcSEcCtD
Torasemide—Dermatitis—Mitomycin—urinary bladder cancer	0.00162	0.00567	CcSEcCtD
Torasemide—Rectal haemorrhage—Epirubicin—urinary bladder cancer	0.00162	0.00566	CcSEcCtD
Torasemide—Headache—Mitomycin—urinary bladder cancer	0.00161	0.00564	CcSEcCtD
Torasemide—Blood uric acid increased—Methotrexate—urinary bladder cancer	0.00159	0.00556	CcSEcCtD
Torasemide—Hyperuricaemia—Epirubicin—urinary bladder cancer	0.00158	0.00551	CcSEcCtD
Torasemide—Tension—Thiotepa—urinary bladder cancer	0.00156	0.00545	CcSEcCtD
Torasemide—Nervousness—Thiotepa—urinary bladder cancer	0.00154	0.00539	CcSEcCtD
Torasemide—Haemoglobin—Gemcitabine—urinary bladder cancer	0.00154	0.00539	CcSEcCtD
Torasemide—Rhinitis—Gemcitabine—urinary bladder cancer	0.00154	0.00538	CcSEcCtD
Torasemide—Haemorrhage—Gemcitabine—urinary bladder cancer	0.00153	0.00536	CcSEcCtD
Torasemide—Nausea—Mitomycin—urinary bladder cancer	0.00153	0.00535	CcSEcCtD
Torasemide—Haemoglobin—Fluorouracil—urinary bladder cancer	0.00152	0.0053	CcSEcCtD
Torasemide—Rhinitis—Fluorouracil—urinary bladder cancer	0.00151	0.00529	CcSEcCtD
Torasemide—Haemorrhage—Fluorouracil—urinary bladder cancer	0.00151	0.00527	CcSEcCtD
Torasemide—Rectal haemorrhage—Doxorubicin—urinary bladder cancer	0.0015	0.00524	CcSEcCtD
Torasemide—Blood uric acid increased—Epirubicin—urinary bladder cancer	0.00149	0.00521	CcSEcCtD
Torasemide—PTGS1—lymph node—urinary bladder cancer	0.00148	0.00974	CbGeAlD
Torasemide—CYP2C19—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00147	0.0129	CbGpPWpGaD
Torasemide—Ventricular tachycardia—Epirubicin—urinary bladder cancer	0.00146	0.00511	CcSEcCtD
Torasemide—Hyperuricaemia—Doxorubicin—urinary bladder cancer	0.00146	0.0051	CcSEcCtD
Torasemide—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.00145	0.00507	CcSEcCtD
Torasemide—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.00145	0.00506	CcSEcCtD
Torasemide—Leukopenia—Thiotepa—urinary bladder cancer	0.00142	0.00497	CcSEcCtD
Torasemide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00142	0.0125	CbGpPWpGaD
Torasemide—CYP2C8—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.0014	0.0123	CbGpPWpGaD
Torasemide—Cough—Thiotepa—urinary bladder cancer	0.00138	0.00484	CcSEcCtD
Torasemide—Blood uric acid increased—Doxorubicin—urinary bladder cancer	0.00138	0.00482	CcSEcCtD
Torasemide—SLC12A1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.00136	0.012	CbGpPWpGaD
Torasemide—Ventricular tachycardia—Doxorubicin—urinary bladder cancer	0.00135	0.00473	CcSEcCtD
Torasemide—PTGS1—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.00135	0.0119	CbGpPWpGaD
Torasemide—Arthralgia—Thiotepa—urinary bladder cancer	0.00135	0.00472	CcSEcCtD
Torasemide—Myalgia—Thiotepa—urinary bladder cancer	0.00135	0.00472	CcSEcCtD
Torasemide—CYP2C9—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00134	0.0118	CbGpPWpGaD
Torasemide—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—urinary bladder cancer	0.0013	0.0115	CbGpPWpGaD
Torasemide—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.00127	0.00443	CcSEcCtD
Torasemide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00127	0.0112	CbGpPWpGaD
Torasemide—CYP2C19—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00125	0.011	CbGpPWpGaD
Torasemide—Erythema multiforme—Etoposide—urinary bladder cancer	0.00124	0.00433	CcSEcCtD
Torasemide—PTGS1—Biological oxidations—GSTZ1—urinary bladder cancer	0.00121	0.0107	CbGpPWpGaD
Torasemide—Leukopenia—Gemcitabine—urinary bladder cancer	0.00119	0.00418	CcSEcCtD
Torasemide—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00118	0.00413	CcSEcCtD
Torasemide—Leukopenia—Fluorouracil—urinary bladder cancer	0.00117	0.00411	CcSEcCtD
Torasemide—Cough—Gemcitabine—urinary bladder cancer	0.00116	0.00407	CcSEcCtD
Torasemide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00115	0.0102	CbGpPWpGaD
Torasemide—CYP2C8—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00115	0.0101	CbGpPWpGaD
Torasemide—PTGS1—Biological oxidations—GSTO2—urinary bladder cancer	0.00115	0.0101	CbGpPWpGaD
Torasemide—PTGS1—Biological oxidations—NAT1—urinary bladder cancer	0.00115	0.0101	CbGpPWpGaD
Torasemide—Dyspepsia—Thiotepa—urinary bladder cancer	0.00114	0.00399	CcSEcCtD
Torasemide—CYP2C9—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00114	0.01	CbGpPWpGaD
Torasemide—Myalgia—Gemcitabine—urinary bladder cancer	0.00114	0.00397	CcSEcCtD
Torasemide—Chest pain—Gemcitabine—urinary bladder cancer	0.00114	0.00397	CcSEcCtD
Torasemide—Arthralgia—Gemcitabine—urinary bladder cancer	0.00114	0.00397	CcSEcCtD
Torasemide—Myalgia—Fluorouracil—urinary bladder cancer	0.00112	0.00391	CcSEcCtD
Torasemide—Chest pain—Fluorouracil—urinary bladder cancer	0.00112	0.00391	CcSEcCtD
Torasemide—Leukopenia—Cisplatin—urinary bladder cancer	0.00111	0.0039	CcSEcCtD
Torasemide—Pain—Thiotepa—urinary bladder cancer	0.00111	0.00387	CcSEcCtD
Torasemide—Constipation—Thiotepa—urinary bladder cancer	0.00111	0.00387	CcSEcCtD
Torasemide—Oedema—Gemcitabine—urinary bladder cancer	0.00109	0.00381	CcSEcCtD
Torasemide—Oedema—Fluorouracil—urinary bladder cancer	0.00107	0.00375	CcSEcCtD
Torasemide—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.00107	0.00373	CcSEcCtD
Torasemide—Hyponatraemia—Epirubicin—urinary bladder cancer	0.00107	0.00373	CcSEcCtD
Torasemide—Gastrointestinal haemorrhage—Epirubicin—urinary bladder cancer	0.00106	0.00371	CcSEcCtD
Torasemide—Myalgia—Cisplatin—urinary bladder cancer	0.00106	0.0037	CcSEcCtD
Torasemide—PTGS1—Biological oxidations—UGT2B7—urinary bladder cancer	0.00105	0.00925	CbGpPWpGaD
Torasemide—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00105	0.00367	CcSEcCtD
Torasemide—CYP2C19—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00103	0.00904	CbGpPWpGaD
Torasemide—CYP2C19—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00102	0.009	CbGpPWpGaD
Torasemide—PTGS1—Overview of nanoparticle effects—PTGS2—urinary bladder cancer	0.00102	0.00899	CbGpPWpGaD
Torasemide—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.00102	0.00357	CcSEcCtD
Torasemide—Leukopenia—Etoposide—urinary bladder cancer	0.00102	0.00357	CcSEcCtD
Torasemide—Hypotension—Gemcitabine—urinary bladder cancer	0.00102	0.00356	CcSEcCtD
Torasemide—Oedema—Cisplatin—urinary bladder cancer	0.00102	0.00355	CcSEcCtD
Torasemide—Loss of consciousness—Etoposide—urinary bladder cancer	0.001	0.0035	CcSEcCtD
Torasemide—Hypotension—Fluorouracil—urinary bladder cancer	0.001	0.0035	CcSEcCtD
Torasemide—Cough—Etoposide—urinary bladder cancer	0.000995	0.00348	CcSEcCtD
Torasemide—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000994	0.00348	CcSEcCtD
Torasemide—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000993	0.00347	CcSEcCtD
Torasemide—PTGS1—Overview of nanoparticle effects—CXCL8—urinary bladder cancer	0.00099	0.00872	CbGpPWpGaD
Torasemide—Dehydration—Epirubicin—urinary bladder cancer	0.000987	0.00345	CcSEcCtD
Torasemide—SLC12A1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000986	0.00869	CbGpPWpGaD
Torasemide—Hyponatraemia—Doxorubicin—urinary bladder cancer	0.000986	0.00345	CcSEcCtD
Torasemide—Insomnia—Gemcitabine—urinary bladder cancer	0.000985	0.00345	CcSEcCtD
Torasemide—Gastrointestinal haemorrhage—Doxorubicin—urinary bladder cancer	0.000982	0.00343	CcSEcCtD
Torasemide—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000976	0.00341	CcSEcCtD
Torasemide—Chest pain—Etoposide—urinary bladder cancer	0.00097	0.00339	CcSEcCtD
Torasemide—Insomnia—Fluorouracil—urinary bladder cancer	0.000969	0.00339	CcSEcCtD
Torasemide—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000966	0.00338	CcSEcCtD
Torasemide—Pancreatitis—Methotrexate—urinary bladder cancer	0.000961	0.00336	CcSEcCtD
Torasemide—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.000955	0.00334	CcSEcCtD
Torasemide—Hypotension—Cisplatin—urinary bladder cancer	0.000949	0.00332	CcSEcCtD
Torasemide—PTGS1—Biological oxidations—CYP4B1—urinary bladder cancer	0.000946	0.00833	CbGpPWpGaD
Torasemide—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000943	0.0033	CcSEcCtD
Torasemide—CYP2C9—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000936	0.00824	CbGpPWpGaD
Torasemide—CYP2C9—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000932	0.00821	CbGpPWpGaD
Torasemide—Pain—Gemcitabine—urinary bladder cancer	0.000932	0.00326	CcSEcCtD
Torasemide—Constipation—Gemcitabine—urinary bladder cancer	0.000932	0.00326	CcSEcCtD
Torasemide—Asthenia—Thiotepa—urinary bladder cancer	0.000929	0.00325	CcSEcCtD
Torasemide—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000925	0.00324	CcSEcCtD
Torasemide—Pain—Fluorouracil—urinary bladder cancer	0.000916	0.0032	CcSEcCtD
Torasemide—Dehydration—Doxorubicin—urinary bladder cancer	0.000913	0.00319	CcSEcCtD
Torasemide—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000911	0.00319	CcSEcCtD
Torasemide—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000902	0.00316	CcSEcCtD
Torasemide—Pancreatitis—Epirubicin—urinary bladder cancer	0.000899	0.00314	CcSEcCtD
Torasemide—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000893	0.00312	CcSEcCtD
Torasemide—Diarrhoea—Thiotepa—urinary bladder cancer	0.000886	0.0031	CcSEcCtD
Torasemide—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000884	0.00309	CcSEcCtD
Torasemide—CYP2C8—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000873	0.00769	CbGpPWpGaD
Torasemide—Hypotension—Etoposide—urinary bladder cancer	0.000869	0.00304	CcSEcCtD
Torasemide—Pain—Cisplatin—urinary bladder cancer	0.000868	0.00304	CcSEcCtD
Torasemide—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000866	0.00303	CcSEcCtD
Torasemide—Dizziness—Thiotepa—urinary bladder cancer	0.000856	0.003	CcSEcCtD
Torasemide—PTGS1—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000849	0.00748	CbGpPWpGaD
Torasemide—PTGS1—Eicosanoid Synthesis—PTGS2—urinary bladder cancer	0.000847	0.00746	CbGpPWpGaD
Torasemide—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000832	0.00291	CcSEcCtD
Torasemide—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000827	0.00289	CcSEcCtD
Torasemide—Vomiting—Thiotepa—urinary bladder cancer	0.000823	0.00288	CcSEcCtD
Torasemide—Rash—Thiotepa—urinary bladder cancer	0.000817	0.00286	CcSEcCtD
Torasemide—Dermatitis—Thiotepa—urinary bladder cancer	0.000816	0.00285	CcSEcCtD
Torasemide—Headache—Thiotepa—urinary bladder cancer	0.000811	0.00284	CcSEcCtD
Torasemide—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000811	0.00283	CcSEcCtD
Torasemide—SLC12A1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000804	0.00708	CbGpPWpGaD
Torasemide—PTGS1—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.0008	0.00704	CbGpPWpGaD
Torasemide—Pain—Etoposide—urinary bladder cancer	0.000795	0.00278	CcSEcCtD
Torasemide—Constipation—Etoposide—urinary bladder cancer	0.000795	0.00278	CcSEcCtD
Torasemide—Haemoglobin—Methotrexate—urinary bladder cancer	0.000788	0.00276	CcSEcCtD
Torasemide—Haemorrhage—Methotrexate—urinary bladder cancer	0.000784	0.00274	CcSEcCtD
Torasemide—CYP2C8—Biological oxidations—GSTZ1—urinary bladder cancer	0.000783	0.00689	CbGpPWpGaD
Torasemide—Asthenia—Gemcitabine—urinary bladder cancer	0.000782	0.00273	CcSEcCtD
Torasemide—CYP2C19—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000779	0.00686	CbGpPWpGaD
Torasemide—CYP2C8—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000772	0.0068	CbGpPWpGaD
Torasemide—Nausea—Thiotepa—urinary bladder cancer	0.000769	0.00269	CcSEcCtD
Torasemide—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000765	0.00268	CcSEcCtD
Torasemide—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00075	0.00262	CcSEcCtD
Torasemide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000745	0.00261	CcSEcCtD
Torasemide—CYP2C8—Biological oxidations—GSTO2—urinary bladder cancer	0.000742	0.00653	CbGpPWpGaD
Torasemide—CYP2C8—Biological oxidations—NAT1—urinary bladder cancer	0.000742	0.00653	CbGpPWpGaD
Torasemide—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000742	0.00259	CcSEcCtD
Torasemide—Haemoglobin—Epirubicin—urinary bladder cancer	0.000738	0.00258	CcSEcCtD
Torasemide—Rhinitis—Epirubicin—urinary bladder cancer	0.000736	0.00257	CcSEcCtD
Torasemide—Haemorrhage—Epirubicin—urinary bladder cancer	0.000734	0.00257	CcSEcCtD
Torasemide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000733	0.00256	CcSEcCtD
Torasemide—CYP2C8—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000732	0.00644	CbGpPWpGaD
Torasemide—Asthenia—Cisplatin—urinary bladder cancer	0.000729	0.00255	CcSEcCtD
Torasemide—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000711	0.00626	CbGpPWpGaD
Torasemide—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.000708	0.00624	CbGpPWpGaD
Torasemide—Dizziness—Fluorouracil—urinary bladder cancer	0.000708	0.00248	CcSEcCtD
Torasemide—CYP2C19—Biological oxidations—GSTZ1—urinary bladder cancer	0.000699	0.00615	CbGpPWpGaD
Torasemide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000695	0.00243	CcSEcCtD
Torasemide—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000694	0.00243	CcSEcCtD
Torasemide—Vomiting—Gemcitabine—urinary bladder cancer	0.000693	0.00242	CcSEcCtD
Torasemide—PTGS1—Overview of nanoparticle effects—TNF—urinary bladder cancer	0.000689	0.00607	CbGpPWpGaD
Torasemide—CYP2C19—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000689	0.00607	CbGpPWpGaD
Torasemide—Rash—Gemcitabine—urinary bladder cancer	0.000687	0.0024	CcSEcCtD
Torasemide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000686	0.0024	CcSEcCtD
Torasemide—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000683	0.00239	CcSEcCtD
Torasemide—Headache—Gemcitabine—urinary bladder cancer	0.000682	0.00239	CcSEcCtD
Torasemide—Vomiting—Fluorouracil—urinary bladder cancer	0.000681	0.00238	CcSEcCtD
Torasemide—Rhinitis—Doxorubicin—urinary bladder cancer	0.000681	0.00238	CcSEcCtD
Torasemide—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000679	0.00238	CcSEcCtD
Torasemide—CYP2C8—Biological oxidations—UGT2B7—urinary bladder cancer	0.000679	0.00598	CbGpPWpGaD
Torasemide—Rash—Fluorouracil—urinary bladder cancer	0.000675	0.00236	CcSEcCtD
Torasemide—Dermatitis—Fluorouracil—urinary bladder cancer	0.000675	0.00236	CcSEcCtD
Torasemide—Headache—Fluorouracil—urinary bladder cancer	0.000671	0.00235	CcSEcCtD
Torasemide—CYP2C8—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000669	0.00589	CbGpPWpGaD
Torasemide—Asthenia—Etoposide—urinary bladder cancer	0.000667	0.00233	CcSEcCtD
Torasemide—CYP2C19—Biological oxidations—GSTO2—urinary bladder cancer	0.000662	0.00583	CbGpPWpGaD
Torasemide—CYP2C19—Biological oxidations—NAT1—urinary bladder cancer	0.000662	0.00583	CbGpPWpGaD
Torasemide—CYP2C19—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000653	0.00575	CbGpPWpGaD
Torasemide—Nausea—Gemcitabine—urinary bladder cancer	0.000647	0.00226	CcSEcCtD
Torasemide—Vomiting—Cisplatin—urinary bladder cancer	0.000646	0.00226	CcSEcCtD
Torasemide—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000642	0.00225	CcSEcCtD
Torasemide—Rash—Cisplatin—urinary bladder cancer	0.00064	0.00224	CcSEcCtD
Torasemide—Dermatitis—Cisplatin—urinary bladder cancer	0.00064	0.00224	CcSEcCtD
Torasemide—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	0.000637	0.00561	CbGpPWpGaD
Torasemide—Diarrhoea—Etoposide—urinary bladder cancer	0.000636	0.00223	CcSEcCtD
Torasemide—Nausea—Fluorouracil—urinary bladder cancer	0.000636	0.00223	CcSEcCtD
Torasemide—PTGS1—Biological oxidations—NAT2—urinary bladder cancer	0.000629	0.00554	CbGpPWpGaD
Torasemide—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000628	0.00553	CbGpPWpGaD
Torasemide—Tension—Epirubicin—urinary bladder cancer	0.000627	0.00219	CcSEcCtD
Torasemide—Nervousness—Epirubicin—urinary bladder cancer	0.000621	0.00217	CcSEcCtD
Torasemide—Dizziness—Etoposide—urinary bladder cancer	0.000615	0.00215	CcSEcCtD
Torasemide—Leukopenia—Methotrexate—urinary bladder cancer	0.000611	0.00214	CcSEcCtD
Torasemide—CYP2C8—Biological oxidations—CYP4B1—urinary bladder cancer	0.000611	0.00538	CbGpPWpGaD
Torasemide—CYP2C19—Biological oxidations—UGT2B7—urinary bladder cancer	0.000606	0.00533	CbGpPWpGaD
Torasemide—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.000604	0.00532	CbGpPWpGaD
Torasemide—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.000604	0.00532	CbGpPWpGaD
Torasemide—Nausea—Cisplatin—urinary bladder cancer	0.000603	0.00211	CcSEcCtD
Torasemide—CYP2C8—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000603	0.00531	CbGpPWpGaD
Torasemide—CYP2C19—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000597	0.00526	CbGpPWpGaD
Torasemide—Cough—Methotrexate—urinary bladder cancer	0.000596	0.00208	CcSEcCtD
Torasemide—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000596	0.00524	CbGpPWpGaD
Torasemide—Vomiting—Etoposide—urinary bladder cancer	0.000591	0.00207	CcSEcCtD
Torasemide—Rash—Etoposide—urinary bladder cancer	0.000587	0.00205	CcSEcCtD
Torasemide—Dermatitis—Etoposide—urinary bladder cancer	0.000586	0.00205	CcSEcCtD
Torasemide—Headache—Etoposide—urinary bladder cancer	0.000583	0.00204	CcSEcCtD
Torasemide—Arthralgia—Methotrexate—urinary bladder cancer	0.000581	0.00203	CcSEcCtD
Torasemide—Chest pain—Methotrexate—urinary bladder cancer	0.000581	0.00203	CcSEcCtD
Torasemide—Myalgia—Methotrexate—urinary bladder cancer	0.000581	0.00203	CcSEcCtD
Torasemide—Tension—Doxorubicin—urinary bladder cancer	0.00058	0.00203	CcSEcCtD
Torasemide—Nervousness—Doxorubicin—urinary bladder cancer	0.000574	0.00201	CcSEcCtD
Torasemide—Syncope—Epirubicin—urinary bladder cancer	0.000573	0.002	CcSEcCtD
Torasemide—Leukopenia—Epirubicin—urinary bladder cancer	0.000572	0.002	CcSEcCtD
Torasemide—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000562	0.00196	CcSEcCtD
Torasemide—Cough—Epirubicin—urinary bladder cancer	0.000558	0.00195	CcSEcCtD
Torasemide—Nausea—Etoposide—urinary bladder cancer	0.000553	0.00193	CcSEcCtD
Torasemide—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.000552	0.00486	CbGpPWpGaD
Torasemide—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000546	0.00191	CcSEcCtD
Torasemide—CYP2C19—Biological oxidations—CYP4B1—urinary bladder cancer	0.000545	0.0048	CbGpPWpGaD
Torasemide—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000545	0.0048	CbGpPWpGaD
Torasemide—Chest pain—Epirubicin—urinary bladder cancer	0.000544	0.0019	CcSEcCtD
Torasemide—Myalgia—Epirubicin—urinary bladder cancer	0.000544	0.0019	CcSEcCtD
Torasemide—Arthralgia—Epirubicin—urinary bladder cancer	0.000544	0.0019	CcSEcCtD
Torasemide—SLC12A1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000543	0.00478	CbGpPWpGaD
Torasemide—CYP2C19—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000538	0.00474	CbGpPWpGaD
Torasemide—PTGS1—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000533	0.0047	CbGpPWpGaD
Torasemide—Syncope—Doxorubicin—urinary bladder cancer	0.00053	0.00185	CcSEcCtD
Torasemide—Leukopenia—Doxorubicin—urinary bladder cancer	0.000529	0.00185	CcSEcCtD
Torasemide—Oedema—Epirubicin—urinary bladder cancer	0.000521	0.00182	CcSEcCtD
Torasemide—Hypotension—Methotrexate—urinary bladder cancer	0.000521	0.00182	CcSEcCtD
Torasemide—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.00052	0.00182	CcSEcCtD
Torasemide—CYP2C8—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000517	0.00455	CbGpPWpGaD
Torasemide—Cough—Doxorubicin—urinary bladder cancer	0.000516	0.0018	CcSEcCtD
Torasemide—Shock—Epirubicin—urinary bladder cancer	0.000513	0.00179	CcSEcCtD
Torasemide—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000511	0.00179	CcSEcCtD
Torasemide—PTGS1—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000509	0.00448	CbGpPWpGaD
Torasemide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000508	0.00178	CcSEcCtD
Torasemide—Insomnia—Methotrexate—urinary bladder cancer	0.000504	0.00176	CcSEcCtD
Torasemide—Chest pain—Doxorubicin—urinary bladder cancer	0.000503	0.00176	CcSEcCtD
Torasemide—Myalgia—Doxorubicin—urinary bladder cancer	0.000503	0.00176	CcSEcCtD
Torasemide—Arthralgia—Doxorubicin—urinary bladder cancer	0.000503	0.00176	CcSEcCtD
Torasemide—PTGS1—Biological oxidations—HPGDS—urinary bladder cancer	0.000503	0.00443	CbGpPWpGaD
Torasemide—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000497	0.00438	CbGpPWpGaD
Torasemide—Dyspepsia—Methotrexate—urinary bladder cancer	0.00049	0.00172	CcSEcCtD
Torasemide—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00049	0.00432	CbGpPWpGaD
Torasemide—PTGS1—Biological oxidations—GSTT1—urinary bladder cancer	0.000488	0.0043	CbGpPWpGaD
Torasemide—Hypotension—Epirubicin—urinary bladder cancer	0.000487	0.0017	CcSEcCtD
Torasemide—Oedema—Doxorubicin—urinary bladder cancer	0.000482	0.00169	CcSEcCtD
Torasemide—Pain—Methotrexate—urinary bladder cancer	0.000476	0.00167	CcSEcCtD
Torasemide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000475	0.00166	CcSEcCtD
Torasemide—Shock—Doxorubicin—urinary bladder cancer	0.000475	0.00166	CcSEcCtD
Torasemide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000472	0.00165	CcSEcCtD
Torasemide—Insomnia—Epirubicin—urinary bladder cancer	0.000472	0.00165	CcSEcCtD
Torasemide—PTGS1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000471	0.00415	CbGpPWpGaD
Torasemide—PTGS1—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.00047	0.00413	CbGpPWpGaD
Torasemide—CYP2C19—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000461	0.00406	CbGpPWpGaD
Torasemide—Dyspepsia—Epirubicin—urinary bladder cancer	0.000459	0.00161	CcSEcCtD
Torasemide—Hypotension—Doxorubicin—urinary bladder cancer	0.000451	0.00158	CcSEcCtD
Torasemide—Pain—Epirubicin—urinary bladder cancer	0.000446	0.00156	CcSEcCtD
Torasemide—Constipation—Epirubicin—urinary bladder cancer	0.000446	0.00156	CcSEcCtD
Torasemide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.00044	0.00154	CcSEcCtD
Torasemide—Insomnia—Doxorubicin—urinary bladder cancer	0.000436	0.00153	CcSEcCtD
Torasemide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000428	0.00377	CbGpPWpGaD
Torasemide—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000425	0.00149	CcSEcCtD
Torasemide—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.00042	0.0037	CbGpPWpGaD
Torasemide—Constipation—Doxorubicin—urinary bladder cancer	0.000413	0.00144	CcSEcCtD
Torasemide—Pain—Doxorubicin—urinary bladder cancer	0.000413	0.00144	CcSEcCtD
Torasemide—CYP2C8—Biological oxidations—NAT2—urinary bladder cancer	0.000406	0.00358	CbGpPWpGaD
Torasemide—CYP2C8—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000401	0.00353	CbGpPWpGaD
Torasemide—Asthenia—Methotrexate—urinary bladder cancer	0.0004	0.0014	CcSEcCtD
Torasemide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000381	0.00133	CcSEcCtD
Torasemide—Asthenia—Epirubicin—urinary bladder cancer	0.000374	0.00131	CcSEcCtD
Torasemide—Dizziness—Methotrexate—urinary bladder cancer	0.000368	0.00129	CcSEcCtD
Torasemide—PTGS1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000363	0.0032	CbGpPWpGaD
Torasemide—CYP2C19—Biological oxidations—NAT2—urinary bladder cancer	0.000363	0.0032	CbGpPWpGaD
Torasemide—CYP2C19—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000358	0.00315	CbGpPWpGaD
Torasemide—Diarrhoea—Epirubicin—urinary bladder cancer	0.000357	0.00125	CcSEcCtD
Torasemide—Vomiting—Methotrexate—urinary bladder cancer	0.000354	0.00124	CcSEcCtD
Torasemide—Rash—Methotrexate—urinary bladder cancer	0.000351	0.00123	CcSEcCtD
Torasemide—Dermatitis—Methotrexate—urinary bladder cancer	0.000351	0.00123	CcSEcCtD
Torasemide—Headache—Methotrexate—urinary bladder cancer	0.000349	0.00122	CcSEcCtD
Torasemide—Asthenia—Doxorubicin—urinary bladder cancer	0.000346	0.00121	CcSEcCtD
Torasemide—Dizziness—Epirubicin—urinary bladder cancer	0.000345	0.00121	CcSEcCtD
Torasemide—PTGS1—Biological oxidations—GSTP1—urinary bladder cancer	0.000338	0.00298	CbGpPWpGaD
Torasemide—Vomiting—Epirubicin—urinary bladder cancer	0.000332	0.00116	CcSEcCtD
Torasemide—Nausea—Methotrexate—urinary bladder cancer	0.000331	0.00116	CcSEcCtD
Torasemide—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000331	0.00291	CbGpPWpGaD
Torasemide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.00033	0.00115	CcSEcCtD
Torasemide—Rash—Epirubicin—urinary bladder cancer	0.000329	0.00115	CcSEcCtD
Torasemide—Dermatitis—Epirubicin—urinary bladder cancer	0.000328	0.00115	CcSEcCtD
Torasemide—Headache—Epirubicin—urinary bladder cancer	0.000327	0.00114	CcSEcCtD
Torasemide—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000326	0.00287	CbGpPWpGaD
Torasemide—CYP2C8—Biological oxidations—HPGDS—urinary bladder cancer	0.000325	0.00286	CbGpPWpGaD
Torasemide—Dizziness—Doxorubicin—urinary bladder cancer	0.000319	0.00112	CcSEcCtD
Torasemide—CYP2C8—Biological oxidations—GSTT1—urinary bladder cancer	0.000315	0.00278	CbGpPWpGaD
Torasemide—PTGS1—Biological oxidations—GSTM1—urinary bladder cancer	0.000311	0.00274	CbGpPWpGaD
Torasemide—Nausea—Epirubicin—urinary bladder cancer	0.00031	0.00108	CcSEcCtD
Torasemide—Vomiting—Doxorubicin—urinary bladder cancer	0.000307	0.00107	CcSEcCtD
Torasemide—Rash—Doxorubicin—urinary bladder cancer	0.000304	0.00106	CcSEcCtD
Torasemide—CYP2C8—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000304	0.00268	CbGpPWpGaD
Torasemide—Dermatitis—Doxorubicin—urinary bladder cancer	0.000304	0.00106	CcSEcCtD
Torasemide—Headache—Doxorubicin—urinary bladder cancer	0.000302	0.00106	CcSEcCtD
Torasemide—PTGS1—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.0003	0.00264	CbGpPWpGaD
Torasemide—CYP2C19—Biological oxidations—HPGDS—urinary bladder cancer	0.00029	0.00255	CbGpPWpGaD
Torasemide—Nausea—Doxorubicin—urinary bladder cancer	0.000287	0.001	CcSEcCtD
Torasemide—CYP2C19—Biological oxidations—GSTT1—urinary bladder cancer	0.000281	0.00248	CbGpPWpGaD
Torasemide—CYP2C19—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000271	0.00239	CbGpPWpGaD
Torasemide—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000264	0.00233	CbGpPWpGaD
Torasemide—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000257	0.00226	CbGpPWpGaD
Torasemide—SLC12A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000254	0.00224	CbGpPWpGaD
Torasemide—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000248	0.00218	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000235	0.00207	CbGpPWpGaD
Torasemide—CYP2C8—Biological oxidations—GSTP1—urinary bladder cancer	0.000218	0.00192	CbGpPWpGaD
Torasemide—CYP2C8—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000215	0.0019	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000209	0.00184	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—GSTZ1—urinary bladder cancer	0.000207	0.00182	CbGpPWpGaD
Torasemide—PTGS1—Selenium Micronutrient Network—TNF—urinary bladder cancer	0.000202	0.00178	CbGpPWpGaD
Torasemide—CYP2C8—Biological oxidations—GSTM1—urinary bladder cancer	0.000201	0.00177	CbGpPWpGaD
Torasemide—CYP2C8—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000198	0.00174	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—GSTO2—urinary bladder cancer	0.000196	0.00173	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—NAT1—urinary bladder cancer	0.000196	0.00173	CbGpPWpGaD
Torasemide—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	0.000195	0.00172	CbGpPWpGaD
Torasemide—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000193	0.0017	CbGpPWpGaD
Torasemide—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000192	0.00169	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000191	0.00168	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—UGT2B7—urinary bladder cancer	0.00018	0.00158	CbGpPWpGaD
Torasemide—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	0.000179	0.00158	CbGpPWpGaD
Torasemide—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000178	0.00157	CbGpPWpGaD
Torasemide—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000177	0.00156	CbGpPWpGaD
Torasemide—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000175	0.00154	CbGpPWpGaD
Torasemide—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000163	0.00144	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—CYP4B1—urinary bladder cancer	0.000162	0.00142	CbGpPWpGaD
Torasemide—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000161	0.00142	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—SLC19A1—urinary bladder cancer	0.000153	0.00135	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—PRSS3—urinary bladder cancer	0.000149	0.00131	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	0.000134	0.00118	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	0.000127	0.00112	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—NAT1—urinary bladder cancer	0.000127	0.00112	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000125	0.0011	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	0.000119	0.00105	CbGpPWpGaD
Torasemide—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000119	0.00105	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—TYMP—urinary bladder cancer	0.000119	0.00105	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	0.000116	0.00102	CbGpPWpGaD
Torasemide—PTGS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000114	0.00101	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	0.000113	0.000997	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—NAT1—urinary bladder cancer	0.000113	0.000997	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000111	0.000981	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	0.000109	0.000959	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—NAT2—urinary bladder cancer	0.000108	0.000948	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	0.000104	0.00092	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	0.000104	0.000912	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	0.000103	0.000909	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—NAT1—urinary bladder cancer	0.000103	0.000909	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000102	0.000894	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	9.87e-05	0.000869	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	9.62e-05	0.000847	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	9.44e-05	0.000832	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	9.33e-05	0.000821	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—RRM2—urinary bladder cancer	9.29e-05	0.000818	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	8.81e-05	0.000776	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—ENO2—urinary bladder cancer	8.6e-05	0.000758	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—HPGDS—urinary bladder cancer	8.6e-05	0.000758	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	8.58e-05	0.000756	CbGpPWpGaD
Torasemide—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.55e-05	0.000753	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	8.5e-05	0.000749	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—GSTT1—urinary bladder cancer	8.34e-05	0.000735	CbGpPWpGaD
Torasemide—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.22e-05	0.000724	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	8.03e-05	0.000707	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	7.83e-05	0.000689	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.71e-05	0.000679	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—TYMP—urinary bladder cancer	7.69e-05	0.000677	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.38e-05	0.00065	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—NAT2—urinary bladder cancer	6.95e-05	0.000612	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—NQO1—urinary bladder cancer	6.94e-05	0.000611	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.88e-05	0.000606	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—TYMP—urinary bladder cancer	6.86e-05	0.000604	CbGpPWpGaD
Torasemide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.73e-05	0.000593	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.59e-05	0.00058	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.27e-05	0.000553	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—TYMP—urinary bladder cancer	6.26e-05	0.000551	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—NAT2—urinary bladder cancer	6.2e-05	0.000546	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.01e-05	0.000529	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—RRM2—urinary bladder cancer	6e-05	0.000528	CbGpPWpGaD
Torasemide—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.87e-05	0.000517	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—GSTP1—urinary bladder cancer	5.78e-05	0.000509	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—NAT2—urinary bladder cancer	5.66e-05	0.000498	CbGpPWpGaD
Torasemide—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.6e-05	0.000493	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	5.56e-05	0.000489	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—ENO2—urinary bladder cancer	5.56e-05	0.000489	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.52e-05	0.000487	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	5.39e-05	0.000475	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—TYMS—urinary bladder cancer	5.38e-05	0.000474	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—RRM2—urinary bladder cancer	5.36e-05	0.000472	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—NCOR1—urinary bladder cancer	5.32e-05	0.000468	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—GSTM1—urinary bladder cancer	5.32e-05	0.000468	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.31e-05	0.000467	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—GPX1—urinary bladder cancer	5.09e-05	0.000448	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—ERCC2—urinary bladder cancer	5e-05	0.00044	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—ENO2—urinary bladder cancer	4.96e-05	0.000437	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	4.96e-05	0.000437	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.93e-05	0.000434	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—RRM2—urinary bladder cancer	4.88e-05	0.00043	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	4.81e-05	0.000424	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.74e-05	0.000417	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—MTHFR—urinary bladder cancer	4.7e-05	0.000414	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	4.52e-05	0.000398	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—ENO2—urinary bladder cancer	4.52e-05	0.000398	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.5e-05	0.000396	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—NQO1—urinary bladder cancer	4.48e-05	0.000394	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	4.39e-05	0.000386	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.35e-05	0.000383	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.32e-05	0.00038	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—NQO1—urinary bladder cancer	4e-05	0.000352	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.88e-05	0.000342	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—PPARG—urinary bladder cancer	3.81e-05	0.000335	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.79e-05	0.000334	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	3.74e-05	0.000329	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—CREBBP—urinary bladder cancer	3.66e-05	0.000322	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—NQO1—urinary bladder cancer	3.65e-05	0.000321	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.61e-05	0.000318	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.54e-05	0.000311	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—TYMS—urinary bladder cancer	3.47e-05	0.000306	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	3.43e-05	0.000302	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	3.43e-05	0.000302	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.38e-05	0.000298	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	3.33e-05	0.000294	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—GPX1—urinary bladder cancer	3.29e-05	0.00029	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	3.23e-05	0.000284	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.23e-05	0.000284	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—TYMS—urinary bladder cancer	3.1e-05	0.000273	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.08e-05	0.000272	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	3.06e-05	0.00027	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	3.06e-05	0.00027	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	3.04e-05	0.000268	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	3.03e-05	0.000267	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—PTGS2—urinary bladder cancer	3e-05	0.000264	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.94e-05	0.000259	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—GPX1—urinary bladder cancer	2.93e-05	0.000258	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	2.88e-05	0.000254	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.83e-05	0.000249	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.79e-05	0.000246	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.79e-05	0.000246	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	2.71e-05	0.000238	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.68e-05	0.000236	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.63e-05	0.000231	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—PTEN—urinary bladder cancer	2.61e-05	0.00023	CbGpPWpGaD
Torasemide—PTGS1—Metabolism—EP300—urinary bladder cancer	2.49e-05	0.000219	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.47e-05	0.000217	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—PPARG—urinary bladder cancer	2.46e-05	0.000217	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	2.36e-05	0.000208	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—PPARG—urinary bladder cancer	2.2e-05	0.000193	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	2.11e-05	0.000186	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2e-05	0.000176	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.94e-05	0.00017	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.92e-05	0.000169	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.73e-05	0.000152	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.69e-05	0.000149	CbGpPWpGaD
Torasemide—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.61e-05	0.000142	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.58e-05	0.000139	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.51e-05	0.000133	CbGpPWpGaD
Torasemide—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.44e-05	0.000127	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.37e-05	0.000121	CbGpPWpGaD
Torasemide—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.31e-05	0.000115	CbGpPWpGaD
